Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Mode and Site of Action of Therapies Targeting Cgrp Signaling Publisher Pubmed



Labastidaramirez A1 ; Caronna E2, 3 ; Gollion C4 ; Stanyer E1, 5 ; Dapkute A6 ; Braniste D7, 8 ; Naghshineh H9 ; Meksa L10 ; Chkhitunidze N11 ; Gudadze T12 ; Pozorosich P2, 3 ; Burstein R13, 14, 15 ; Hoffmann J1, 16
Authors

Source: Journal of Headache and Pain Published:2023


Abstract

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed. © 2023, Springer-Verlag Italia S.r.l., part of Springer Nature.
1. Future Targets for Migraine Treatment Beyond Cgrp, Journal of Headache and Pain (2023)
3. The Sense of Stopping Migraine Prophylaxis, Journal of Headache and Pain (2023)
Experts (# of related papers)
Other Related Docs
12. A Review: Fda-Approved Fluorine-Containing Small Molecules From 2015 to 2022, European Journal of Medicinal Chemistry (2023)